A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
Conditions : Essential Hypertension Interventions : Drug: QR12000 Compound Tablets 75 mg; Drug: QR12000 Compound Tablets 75 mg placebo; Drug: QR12000 Compound Tablets 150 mg; Drug: QR12000 Compound…
Read the full article3d agoen
You might also wanna read
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
clinicaltrials.gov·just now
Pooled analysis of over 120 clinical trials finds no increased cardiovascular risk with sildenafil (Viagra)
pubmed.ncbi.nlm.nih.gov·20m agoThe future of US psychedelic medicine is carved out by the FDA
refractor.io·27m ago
Umoja Receives FDA IND Clearance for CD22-Directed In Vivo CAR-T Therapy
PackGene Biotech·1h ago
Johnson & Johnson Discontinues JNJ-1887 Gene Therapy Program for Geographic Atrophy
PackGene Biotech·1h ago
Cancro al pancreas, la speranza di un vaccino per prevenirlo: lo studio e i primi test
Adnkronos·3h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.